Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines: Table 1.

Statistical Power Analysis for the Behavioral Sciences

1989 • 83,906 citations

Statistical power analysis for the behavioral sciences

1990 • 65,781 citations

Statistical Power Analysis for the Behavioral Sciences (2nd ed.).

1989 • 28,417 citations

New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

1983 • 7,404 citations

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

2001 • 6,888 citations

Axonal Transection in the Lesions of Multiple Sclerosis

1998 • 4,007 citations

Defining the clinical course of multiple sclerosis

1996 • 3,606 citations

More powerful procedures for multiple significance testing

1990 • 2,572 citations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Cognitive dysfunction in multiple sclerosis.: I. Frequency, patterns, and prediction

1991 • 2,046 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 1,908 citations

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 • 1,903 citations

Axonal damage in acute multiple sclerosis lesions

1997 • 1,543 citations

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

2000 • 1,497 citations

THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY

1989 • 1,387 citations

Relapses and Progression of Disability in Multiple Sclerosis

2000 • 1,285 citations

A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis

1992 • 1,254 citations

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

1993 • 1,227 citations

The natural history of multiple sclerosis:a geographically based study

1999 • 1,190 citations

Procedures for Comparing Samples with Multiple Endpoints

1984 • 1,166 citations

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1999 • 1,144 citations

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

2001 • 1,077 citations

Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

1998 • 931 citations

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease

1999 • 878 citations

Cognitive dysfunction in multiple sclerosis.

1991 • 876 citations

Intensive Immunosuppression in Progressive Multiple Sclerosis

1983 • 813 citations

Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines: Table 1.

2002 • 812 citations

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

1999 • 728 citations

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

2001 • 697 citations

THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY

1989 • 597 citations

European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

2001 • 595 citations

The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis

1993 • 572 citations

PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

2001 • 563 citations

The epidemiology of multiple sclerosis

2016 • 505 citations

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

1998 • 504 citations

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis

1999 • 490 citations

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

1998 • 483 citations

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

2001 • 471 citations

A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis

1987 • 465 citations

Randomized controlled trial of interferon-beta-1a in secondary progressive MS

2001 • 461 citations

Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosis

1999 • 384 citations

Recommendations from the national multiple sclerosis society clinical outcomes assessment task force

1997 • 371 citations

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.

1987 • 361 citations

Influence of the Carbohydrate Moiety on the Stability of Glycoproteins

1996 • 339 citations

Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

1998 • 334 citations

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

1998 • 332 citations

Cladribine and progressive MS

2000 • 317 citations

Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis

1995 • 309 citations

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial

1990 • 302 citations

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

1998 • 292 citations

Cladribine in treatment of chronic progressive multiple sclerosis

1994 • 284 citations

Optic neuritis

1995 • 281 citations

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1997 • 274 citations

Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses

1998 • 261 citations

Cooperative study in the evaluation of therapy in multiple sclerosis

1970 • 256 citations

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

1999 • 254 citations

Mechanisms of action of glatiramer acetate in multiple sclerosis

2001 • 252 citations

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis

1993 • 249 citations

A neurologic rating scale (NRS) for use in multiple sclerosis

1984 • 245 citations

The Epidemiology of Multiple Sclerosis

1997 • 238 citations

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions

1993 • 237 citations

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

1997 • 234 citations

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

2000 • 233 citations

Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

2000 • 223 citations

Overview of azathioprine treatment in multiple sclerosis

1991 • 222 citations

McAlpine's Multiple Sclerosis

1991 • 211 citations

The treatment of chronic progressive multiple sclerosis with cladribine.

1996 • 208 citations

Risk of cancer from azathioprine therapy in multiple sclerosis

1996 • 203 citations

THE PROBLEM OF MULTIPLE INFERENCE IN STUDIES DESIGNED TO GENERATE HYPOTHESES

1985 • 194 citations

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

2000 • 191 citations

High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect.

1992 • 190 citations

Total brain N -acetylaspartate

2000 • 188 citations

High‐dose intravenous methylprednisolone in the treatment of multiple sclerosis

1986 • 177 citations

A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1991 • 176 citations

Double‐blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis

1989 • 170 citations

Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.

1992 • 165 citations

Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male Volunteers

1996 • 160 citations

Chronic progressive multiple sclerosis

1985 • 151 citations

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.

1993 • 146 citations

A Double‐Blind, Placebo‐Controlled, Randomized Trial of Cladribine in Relpaasing‐Remitting Multiple Sclerosis

1999 • 143 citations

Quantitative MRI changes in gadolinium‐DTPA enhancement after high‐dose intravenous methylprednisolone in multiple sclerosis

1991 • 143 citations

A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis

1999 • 141 citations

Interrater Reliability in Assessing Functional Systems and Disability on the Kurtzke Scale in Multiple Sclerosis

1988 • 139 citations

Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS

1989 • 131 citations

Practice parameter: The usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review)

2000 • 130 citations

Molecular pathogenesis of multiple sclerosis

1999 • 124 citations

A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials

1999 • 123 citations

A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis

1998 • 112 citations

A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

1989 • 111 citations

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

1992 • 111 citations

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates

2001 • 98 citations

The effect of high‐dose steroids on MRI gadolinium enhancement in acute demyelinating lesions

1991 • 97 citations

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

1991 • 94 citations

The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis

1998 • 94 citations

The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis

1991 • 88 citations

A comparative study of the relative bioavailability of different interferon beta preparations

2000 • 86 citations

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

2000 • 84 citations

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.

1991 • 82 citations

The Immunobiology of Multiple Sclerosis: An Autoimmune Disease of the Central Nervous System

1999 • 82 citations

Pharmacodynamic Comparison of Single Doses of IFN-beta 1a and IFN-beta 1b in Healthy Volunteers

1999 • 81 citations

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates

2001 • 79 citations

Interferon immunogenicity: technical evaluation of interferon-alpha 2a.

1997 • 71 citations

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration

1996 • 64 citations

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.

1993 • 59 citations

Perils and Pitfalls in the Interpretation of Clinical Trials: A Reflection on the Recent Experience in Multiple Sclerosis

1999 • 58 citations

Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis

1994 • 57 citations

A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year

1994 • 56 citations

Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers.

1997 • 56 citations

A prospective, open‐label treatment trial to compare the effect of IFN β‐1a (Avonex), IFNβ‐1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing‐remitting multiple sclerosis

2001 • 55 citations

A messy necessary end

2001 • 52 citations

A questionnaire to assess neurological impairment in multiple sclerosis

1998 • 50 citations

The extended disability status scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis

1993 • 49 citations

A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis

1994 • 45 citations

Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis

1995 • 43 citations

Double-Blind Randomized Trial of ACTH versus Dexamethasone versus Methylprednisolone in Multiple Sclerosis Bouts

1989 • 43 citations

Monitoring azathioprine therapy in myasthenia gravis

1986 • 36 citations

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: Plight of the practicing neurologist

1997 • 32 citations

A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results

1997 • 30 citations

A possible harmful late effect of methylprednisolone therapy on a time cluster of optic neuritis

1989 • 22 citations

Invited Commentary: p Values, Hypothesis Tests, and Likelihood

1993 • 13 citations

Cyclophosphamide in chronic progressive multiple sclerosis.

1987 • 12 citations

European Journal of Neurology: five years already

1998 • 10 citations

Author's Response to “Invited Commentary: p Values, Hypothesis Tests, and Likelihood”

1993 • 5 citations